Edition:
India

People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

85.81USD
14 Jun 2019
Change (% chg)

$-11.54 (-11.85%)
Prev Close
$97.35
Open
$98.88
Day's High
$100.55
Day's Low
$85.49
Volume
227,395
Avg. Vol
79,652
52-wk High
$127.74
52-wk Low
$64.25

Golumbeski, George 

Dr. George S. Golumbeski, Ph.D., is an Independent Director of the Company. Dr. Golumbeski has been the Executive Vice President for Innovation since 2017 for Celgene Corporation, a biotechnology company, where he was previously Executive Vice President of Business Development since 2009, responsible for the full array of business development activities and focused primarily within the therapeutic areas of oncology and inflammation. From 2008 to 2009, Dr. Golumbeski served as the CEO of Nabriva Therapeutics AG. Prior to Nabriva, Dr. Golumbeski served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. Earlier in his career, Dr. Golumbeski held senior positions at Elan Pharmaceuticals and at Schwarz Pharma. He currently serves on the board of directors of Acceleron Pharma, Inc., a public biotechnology company. Dr. Golumbeski received a BA in biology from the University of Virginia and a Ph.D. in genetics from the University of Wisconsin-Madison.

Basic Compensation

Total Annual Compensation, USD 60,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 306,690
Fiscal Year Total, USD 366,690

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Bruce Carter

394,190

Jay Luly

4,508,740

Paul Mellett

1,421,280

Yat Sun Or

1,524,000

Nathaniel Gardiner

1,376,110

Nathalie Adda

1,514,080
As Of  30 Sep 2018